Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.45 |
| ▸ | PPARA | Q07869 | 11/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL4824344 | 1.00 | PPARG (0.45) | PPARGPPARATSHRHPGDPPARD | |
| Arginine SCHEMBL4826312 | 0.96 | PPARG (0.44) | PPARGPPARATSHRHPGDPPARD | |
| Arginine SCHEMBL4826319 | 0.96 | PPARG (0.44) | PPARGPPARATSHRHPGDPPARD | |
| SCHEMBL4824348 | 0.91 | PPARG (0.38) | PPARGPPARATSHRHPGDLMNA | |
| Arginine SCHEMBL4822377 | 0.90 | PPARG (0.50) | PPARGPPARAPPARD | |
| Arginine SCHEMBL4867119 | 0.90 | PPARG (0.52) | PPARGPPARAPPARD | |
| Arginine SCHEMBL4867150 | 0.90 | PPARG (0.52) | PPARGPPARAPPARD | |
| Arginine SCHEMBL4822370 | 0.90 | PPARG (0.50) | PPARGPPARAPPARD | |
| Arginine SCHEMBL4824934 | 0.89 | PPARG (0.40) | PPARGPPARATSHRHPGD | |
| Arginine SCHEMBL4824931 | 0.89 | PPARG (0.40) | PPARGPPARATSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365064-B2 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-29 | — | — | US | disclosed |
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113368-A1 | Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them | CYP3A5, HBZ, CYP4Z1 | PPARG 86/4885PPARA 113/4885TSHR 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.